Expression of extracellular matrix-degrading proteins in classic, atypical, and anaplastic meningiomas

Pathology Research and Practice

Volumn 202, Issue 5, 2006, Pages 365-372

  von Randow, A Josefine U ^a   Schindler, Susanne ^b   Tews, Dominique S ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b MACNEAL HOSPITAL   (United States)

Author keywords

Degrading proteins; Extracellular matrix; Invasion; Meningiomas

Indexed keywords

CATHEPSIN D; GELATINASE A; GELATINASE B;

ARTICLE; BENIGN TUMOR; CANCER GRADING; CANCER INVASION; CONTROLLED STUDY; DRUG TARGETING; ENZYME ANALYSIS; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MENINGIOMA; PROTEIN EXPRESSION; SCREENING; STATISTICAL ANALYSIS; TUMOR CELL; TUMOR CLASSIFICATION;

EID: 33645953655     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2006.01.012     Document Type: Article

References (48)

1. Andersson U., Malmer B., Bergenheim A.T., Brannstorm T., and Henriksson R. Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin. Neuropathol. 23 (2004) 21-27
2. Bellon G., Caulet T., Cam Y., Pluot M., Poulin G., Pytlinska M., and Bernard M.H. Immunohistochemical localisation of macromolecules of the basement membrane and extracellular matrix of human gliomas and meningiomas. Acta Neuropathol. 66 (1985) 245-252
3. Castilla E.A., Prayson R.A., Abramovich C.M., and Cohen M.L. Immunohistochemical expression of cathepsin D in meningiomas. Am. J. Clin. Pathol. 119 (2003) 123-128
4. Chang C., and Werb Z. The many faces of metalloproteinases: cell growth, invasion, angiogenesis and metastasis. Trends Cell. Biol. 11 (2001) S37-S43
5. Cuevas I.C., Slocum A.L., Jun P., Costello J.F., Bollen A.W., Riggins G.J., McDermott M.W., and Lal A. Meningioma transcript profiles reveal deregulated Notch signalling pathway. Cancer Res. 65 (2005) 5070-5075
6. Das A., Tan W.L., and Smith D.R. Expression of extracellular matrix markers in benign meningiomas. Neuropathology 23 (2003) 275-281
7. Diment S., and Stahl P. Macrophages endosomes contain proteases which degrade endocytosed protein ligands. J. Biol. Chem. 260 (1985) 15311-15317
8. Duffy M.J. Proteases as prognostic markers in cancer. Clin. Cancer Res. 2 (1996) 613-618
9. Egeblad M., and Werb Z. New functions for the metalloproteinases in cancer progression. Nat. Rev. Cancer 2 (2002) 163-176
10. Ennis B.W., and Matrisian L.M. Matrix degrading metalloproteinases. J. Neurooncol. 18 (1994) 105-109
11. Guthrie B.L., Carabell S.C., and Laws E.R. Radiation therapy for intracranial meningiomas. In: Al-Mefty O. (Ed). Meningiomas (1990), Raven Press, New York 255-262
12. Halaka A.N., Bunning R.A., Bird C.C., Gibson M., and Reynold J.J. Production of collagenase and inhibitor (TIMP) by intracranial tumors and dura in vitro. J. Neurosurg. 59 (1983) 461-466
13. Jaalinoja J., Herva R., Korpela M., Hoyhtya M., and Turpeeniemi-Hujanen T. Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J. Neurooncol. 46 (2000) 81-90
14. John A., and Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol. Oncol. Res. 7 (2001) 14-23
15. Jones T.R., Ruoslahti E., Schold S.C., and Bigner D.D. Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas. Cancer Res. 42 (1982) 168-177
16. Kachra Z., Beaulieu E., Delbecchi L., Mousseau N., Berthelet F., Moumdjian R., Del Maestro R., and Beliveau R. Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin. Exp. Metast. 17 (1999) 555-566
17. Kalala J.P., Maes L., Vandenbroecke C., and de Ridder L. The hTERT protein as a marker for malignancy in meningiomas. Oncol. Rep. 13 (2005) 273-277
18. Kieseier B.C., Kiefer R., Clements J.M., Miller K., Wells G.M., Schweitzer T., Gearing A.J., and Hartung H.P. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121 (1998) 159-166
19. Kirches E., Grunewald J., von Bossanyi P., Szibor R., Plate I., Kruger S., Warich-Kirches M., and Dietzmann K. Expression of matrix metalloproteinases in a series of 12 meningiomas. Clin. Neuropathol. 20 (2001) 26-30
20. Levicar N., Nutall R.K., and Lah T.T. Proteases in brain tumour progression. Acta Neurochir. 145 (2003) 825-838
21. Liu Y., Pang J.C., Dong S., Mao B., Poon W.S., and Ng H.K. Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum. Pathol. 36 (2005) 416-425
22. Lusis E.A., Chicoine M.R., and Perry A. High throughput screening of meningioma biomarkers using a tissue microarray. J. Neurooncol. 73 (2005) 219-223
23. Lusis E.A., Watson M.A., Chicoine M.R., Lyman M., Roerig P., Reifenberger G., Gutmann D.H., and Perry A. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res. 65 (2005) 7121-7126
24. Maier H., Ofner D., Hittmair A., Kitz K., and Budka H. Classic, atypical, and anaplastic meningioma: three histopathologic subtypes of clinical relevance. J. Neurosurg. 77 (1992) 616-623
25. Maor M.H. Radiotherapy for meningiomas. J. Neurooncol. 29 (1996) 261-267
26. Marosi C., Hassler M., and Rössler K. Guidelines to the treatment of meningioma. Forum (Genova) 13 (2003) 76-89
27. Mawrin C., Sasse T., Kirches E., Kropf S., Schneider T., Grimm C., Pambor C., Vorwerk C.K., Firsching R., Lendeckel U., and Dietzmann K. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningomas. Clin. Cancer Res. 11 (2005) 4074-4082
28. Mizoue T., Kawamoto H., Arita K., Tominaga A., and Kurisu K. Secretion of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by meningiomas detected by cell immunoblot analysis. Acta Neurochir. 141 (1999) 481-486
29. Morelli C., Campioni K., Parolin C., Palu G., and Tognon M. Activity of the matrix metalloproteinase-9 promoter in human normal and tumor cells. J. Cell Physiol. 199 (2004) 126-133
30. Nakagawa T., Kubota T., Kabuto M., Sato K., Kawano H., and Hayakawa Y. Production of matrix metalloproteinases and tissue inhibitor metalloproteinases-1 by human brain tumors. J. Neurosurg. 81 (1994) 69-77
31. Nakagawa T., Kubota T., Kabuto M., Fujimoto N., and Okada Y. Secretion of matrix metalloproteinase-2 (72 kDa gelatinase/type IV collagenase=gelatinase A) by malignant glioma human cell lines: implications for the growth and cellular invasion of the extracellular matrix. J. Neurooncol. 28 (1995) 13-24
32. Nordqvist A.C., Smurawa H., and Mathiesen T. Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema. J. Neurosurg. 95 (2001) 839-844
33. Okada M., Miyake K., Matsumoto Y., Kawai N., Kunishio K., and Nagao S. Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas. J. Neurooncol. 66 (2004) 29-37
34. Paek S.H., Kim C.Y., Kim Y.Y., Park I.A., Kim M.S., Kim D.G., and Jung H.W. Correlation of clinical and biological parameters with peritumoral edema in meningioma. J. Neurooncol. 60 (2002) 235-245
35. Palma L., Celli P., Franco C., Carvoni L., and Cantore G. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J. Neurosurg. 86 (1997) 793-800
36. Robson D.K., Ironside J.W., Reid W.A., and Bogue P.R. Immunolocalisation of cathepsin D in the human central nervous system and central nervous system neoplasms. Neuropathol. Appl. Neurobiol. 16 (1990) 39-44
37. Rooprai H.K., van Meter T.E., Robinson D.S., King A., Rucklidge G.J., and Pilkington G.J. Expression of MMP-2 and -9 in short-term cultures of meningioma: influence of histological subtypes. Int. J. Mol. Med. 12 (2003) 977-981
38. Schiffer D., Ghimenti C., and Fiano V. Absence of histological signs of tumor progression in recurrences of completely resected meningiomas. J. Neurooncol. 73 (2005) 125-130
39. Siddique K., Yanamandra N., Gujrati M., Dinh D., Rao J.S., and Olivero W. Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas. Int. J. Oncol. 22 (2003) 289-294
40. Sivaparvathi M., Sawaya R., Chintala S.K., Go Y., Gokaslan Z.L., and Roa J.S. Expression of cathepsin D during the progression of human gliomas. Neurosci. Lett. 208 (1996) 171-174
41. Stetler-Stevenson W.G., Liotta L.A., and Kleiner Jr. D.E. Extracellular matrix: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 15 (1993) 1434-1441
42. Tews D.S. Adhesive and invasive features in gliomas. Pathol. Res. Pract. 196 (2000) 701-711
43. Tews D.S., Fleissner C., Tiziani B., and Gaumann A.K. Intrinsic expression of drug resistance-associated factors in meningiomas. Appl. Immunohistochem. Mol. Morph. 9 (2001) 242-249
44. Tews D.S., and Nissen A. Expression of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors. Invas. Metast. 18 (1998-99) 271-284
45. Trinkaus M., Vranic A., Dolenc V.V., and Lah T.T. Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas. Int. J. Biol. Markers 20 (2005) 50-59
46. Warich M., von Bossanyi P., and Dietzmann K. Expression of cathepsin D in human astrocytic neoplasias. Gen. Diagn. Pathol. 141 (1995) 93-96
47. Wrobel G., Roerig P., Kokocinski F., Neben K., Hahn M., Reifenberger G., and Lichter P. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int. J. Cancer 114 (2005) 249-256
48. Yamamoto M., Mohanam S., Sawaya R., Fuller G.N., Seiki M., Sato H., Gokaslan Z.L., Liotta L.A., Nocolson G.L., and Rao J.S. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res. 56 (1996) 384-392